Voyager Therapeutics, Inc. – NASDAQ:VYGR

Voyager Therapeutics stock price today

$3.54
-2.2
-38.33%
Financial Health
0
1
2
3
4
5
6
7
8
9

Voyager Therapeutics stock price monthly change

-34.55%
month

Voyager Therapeutics stock price quarterly change

-34.55%
quarter

Voyager Therapeutics stock price yearly change

-34.02%
year

Voyager Therapeutics key metrics

Market Cap
307.54M
Enterprise value
N/A
P/E
-6.71
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
3.73
Price/Book
5.18
PEG ratio
-0.18
EPS
-0.01
Revenue
119.04M
EBITDA
-12.49M
Income
-3.04M
Revenue Q/Q
-87.03%
Revenue Y/Y
-21.26%
Profit margin
-56.6%
Oper. margin
-62%
Gross margin
0.87%
EBIT margin
-62%
EBITDA margin
-10.49%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Voyager Therapeutics stock price history

Voyager Therapeutics stock forecast

Voyager Therapeutics financial statements

Average Price Target
Last Year

$18

Potential upside: 408.47%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR): Profit margin
Jun 2023 4.85M -22.20M -457.61%
Sep 2023 4.61M -25.90M -561.36%
Dec 2023 90.06M 56.39M 62.62%
Mar 2024 19.51M -11.33M -58.05%
Voyager Therapeutics, Inc. (NASDAQ:VYGR): Earnings per share (EPS)
2024-02-28 -0.59 1.25
Voyager Therapeutics, Inc. (NASDAQ:VYGR): Debt to assets
Jun 2023 315536000 116.51M 36.92%
Sep 2023 294653000 118.43M 40.19%
Dec 2023 351281000 114.96M 32.73%
Mar 2024 469592000 128.70M 27.41%
Voyager Therapeutics, Inc. (NASDAQ:VYGR): Cash Flow
Jun 2023 -835K -24.66M 1.54M
Sep 2023 -21.05M -158.30M 331K
Dec 2023 -25.86M 26.83M 2.56M
Mar 2024 58.76M -96.06M 112.85M

Voyager Therapeutics alternative data

Voyager Therapeutics, Inc. (NASDAQ:VYGR): Employee count
Aug 2023 125
Sep 2023 125
Oct 2023 125
Nov 2023 125
Dec 2023 125
Jan 2024 125
Feb 2024 125
Mar 2024 162
Apr 2024 162
May 2024 162
Jun 2024 162
Jul 2024 162

Voyager Therapeutics other data

19.17% -38.59%
of VYGR is owned by hedge funds
7.35M -15.50M
shares is hold by hedge funds

Voyager Therapeutics, Inc. (NASDAQ:VYGR): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 3809
Feb 2024 0 24730
Apr 2024 0 13472
Oct 2024 0 5999
Dec 2024 0 6500
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SWARTZ ROBIN officer: COO&CBO
Common Stock 6,500 $5.65 $36,725
Sale
FAHEY SANDELL JACQUELYN officer: Chief Legal Officer
Common Stock 5,999 $5.82 $34,914
Sale
SWARTZ ROBIN officer: Chief Operating Officer
Common Stock 1,357 $9.88 $13,407
Sale
SANDROCK ALFRED director, officer: President an..
Common Stock 12,115 $9.86 $119,454
Sale
SWARTZ ROBIN officer: Chief Operating Officer
Common Stock 3,966 $7.45 $29,547
Sale
SANDROCK ALFRED director, officer: President an..
Common Stock 13,033 $7.46 $97,226
Sale
PFREUNDSCHUH PETER P. officer: Chief Fi.. Common Stock 3,764 $7.46 $28,079
Sale
CARTER TODD ALFRED officer: Chief Scientific Officer
Common Stock 3,365 $7.47 $25,137
Sale
CARTER TODD ALFRED officer: Chief Scientific Officer
Common Stock 602 $7.68 $4,623
Sale
SWARTZ ROBIN officer: Chief Operating Officer
Common Stock 2,543 $7.15 $18,182
Patent
Grant
Filling date: 16 Oct 2018 Issue date: 6 Sep 2022
Application
Filling date: 24 Jul 2020 Issue date: 1 Sep 2022
Application
Filling date: 29 Apr 2020 Issue date: 4 Aug 2022
Application
Filling date: 22 Mar 2022 Issue date: 7 Jul 2022
Application
Filling date: 6 Dec 2021 Issue date: 23 Jun 2022
Application
Filling date: 1 Jun 2021 Issue date: 23 Jun 2022
Application
Filling date: 29 Apr 2020 Issue date: 2 Jun 2022
Application
Filling date: 4 Nov 2021 Issue date: 26 May 2022
Grant
Filling date: 28 Apr 2017 Issue date: 10 May 2022
Application
Filling date: 8 Oct 2021 Issue date: 28 Apr 2022
Insider Compensation
Mr. G. Andre Turenne (1974) Advisor
$873,480
Mr. Robert W. Hesslein (1953) Senior Vice President & Gen. Counsel $580,650
Mr. Michael J. Higgins M.B.A. (1962) Interim Chief Executive Officer, Pres & Chairman
$90,000
Dr. Glenn F. Pierce M.D., Ph.D. (1956) Independent Director, Interim Chief Scientific Officer & Chief Medical Officer $51,500
Dr. Steven M. Paul M.D. (1951) Executive Science Advisor & Director $44,000
Tuesday, 17 December 2024
zacks.com
Tuesday, 3 December 2024
zacks.com
Friday, 29 November 2024
https://thefly.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 28 October 2024
zacks.com
Monday, 7 October 2024
zacks.com
Thursday, 29 August 2024
globenewswire.com
globenewswire.com
Monday, 26 August 2024
seekingalpha.com
Thursday, 8 August 2024
investorplace.com
Wednesday, 7 August 2024
globenewswire.com
Tuesday, 6 August 2024
zacks.com
globenewswire.com
Tuesday, 23 July 2024
globenewswire.com
Tuesday, 9 July 2024
globenewswire.com
Thursday, 13 June 2024
globenewswire.com
globenewswire.com
Friday, 7 June 2024
seekingalpha.com
Sunday, 2 June 2024
seekingalpha.com
Monday, 20 May 2024
https://www.defenseworld.net
Thursday, 16 May 2024
globenewswire.com
Tuesday, 14 May 2024
seekingalpha.com
Monday, 13 May 2024
Zacks Investment Research
Monday, 6 May 2024
GlobeNewsWire
Wednesday, 1 May 2024
Zacks Investment Research
Monday, 22 April 2024
GlobeNewsWire
  • What's the price of Voyager Therapeutics stock today?

    One share of Voyager Therapeutics stock can currently be purchased for approximately $3.54.

  • When is Voyager Therapeutics's next earnings date?

    Unfortunately, Voyager Therapeutics's (VYGR) next earnings date is currently unknown.

  • Does Voyager Therapeutics pay dividends?

    No, Voyager Therapeutics does not pay dividends.

  • How much money does Voyager Therapeutics make?

    Voyager Therapeutics has a market capitalization of 307.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 511.16% to 250.01M US dollars. Voyager Therapeutics earned 132.33M US dollars in net income (profit) last year or $1.25 on an earnings per share basis.

  • What is Voyager Therapeutics's stock symbol?

    Voyager Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VYGR".

  • What is Voyager Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Voyager Therapeutics?

    Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Voyager Therapeutics's key executives?

    Voyager Therapeutics's management team includes the following people:

    • Mr. G. Andre Turenne Advisor(age: 51, pay: $873,480)
    • Mr. Robert W. Hesslein Senior Vice President & Gen. Counsel(age: 72, pay: $580,650)
    • Mr. Michael J. Higgins M.B.A. Interim Chief Executive Officer, Pres & Chairman(age: 63, pay: $90,000)
    • Dr. Glenn F. Pierce M.D., Ph.D. Independent Director, Interim Chief Scientific Officer & Chief Medical Officer(age: 69, pay: $51,500)
    • Dr. Steven M. Paul M.D. Executive Science Advisor & Director(age: 74, pay: $44,000)
  • How many employees does Voyager Therapeutics have?

    As Jul 2024, Voyager Therapeutics employs 162 workers.

  • When Voyager Therapeutics went public?

    Voyager Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 11 Nov 2015.

  • What is Voyager Therapeutics's official website?

    The official website for Voyager Therapeutics is voyagertherapeutics.com.

  • Where are Voyager Therapeutics's headquarters?

    Voyager Therapeutics is headquartered at 75 Sidney Street, Cambridge, MA.

  • How can i contact Voyager Therapeutics?

    Voyager Therapeutics's mailing address is 75 Sidney Street, Cambridge, MA and company can be reached via phone at 857 259 5340.

  • What is Voyager Therapeutics stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Voyager Therapeutics in the last 12 months, the avarage price target is $18. The average price target represents a 408.47% change from the last price of $3.54.

Voyager Therapeutics company profile:

Voyager Therapeutics, Inc.

voyagertherapeutics.com
Exchange:

NASDAQ

Full time employees:

162

Industry:

Biotechnology

Sector:

Healthcare

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

75 Sidney Street
Cambridge, MA 02139

CIK: 0001640266
ISIN: US92915B1061
CUSIP: 92915B106